MedTrace Logo

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

NCT06773195 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-04-03

No results posted yet for this study

Summary

The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis. The researchers will test different doses of ulixertinib to find the highest dose that causes few or mild side effects in participants when given in combination with ruxolitinib.

Conditions

Interventions

DRUG

Ulixertinib

There are 3 planned dose levels of ulixertinib(450 mg BID, 300 mg BID, or 150 mg BID)

DRUG

Ruxolitinib

Ruxolitinib for 28 day cycles.

Sponsors & Collaborators

Principal Investigators

  • Raajit Rampal, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-07
Primary Completion
2028-01-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06773195 on ClinicalTrials.gov